Adrenarche unmasks compound heterozygous 3β-hydroxysteroid dehydrogenase deficiency: c.244G>A (p.Ala82Thr) and the novel 931C>T (p.Gln311*) variant in a non-salt wasting, severely undervirilised 46XY DOI 10.1515/jpem-2016-0348 Received September 1, 2016 accepted December 19, 2016; previously published online February 16, 2017 Abstract: 3β-Hydroxysteroid dehydrogenase type II deficiency (3βHSD2) congenital adrenal hyperplasia is a rare cause of ambiguous genitalia, resulting in abnormal virilisation in both 46XY and 46XX. We describe a case of 46XY ambiguous genitalia that was misdiagnosed as androgen insensitivity syndrome. The correct diagnosis was made after adrenarche. Genotyping demonstrated compound heterozygosity in two alleles, the previously described c.244G>A (p.Ala82Thr), and a novel 931C>T(p.Gln311*) variant. We suggest that adrenarche unmasked the condition by driving cortisol production to rates that caused the mutant 3βHSD2 enzyme to become rate limiting for cortisol production. This case illustrates how markedly different the effects of this condition may be on androgen production compared with glucocorticoid and mineralocorticoid production. It also demonstrates how current guidelines based on urinary steroids and cortisol sufficiency may not arrive at the correct diagnosis, and underlines the importance of gene testing in the work-up of disorders of sexual differentiation.
Introduction
Adrenarche is still described as one of the least understood of human endocrine developmental events. Whilst adreno-cortico-tropic hormone (ACTH) has been considered an essential hormone for the development of adrenarche, the observation that ACTH and cortisol levels remain constant throughout adrenarche despite the rise in adrenal androgens have caused some to argue that there must be another stimulator for adrenarche [1] .
We describe a case of biochemical unmasking of 3β-hydroxysteroid dehydrogenase type II deficiency (3βHSD2) after infancy. The hypothesis generated through this case focuses on enzyme activities in the zona fasciculata. Whilst ACTH and cortisol levels in serum remain constant throughout adrenarche, there is an increased metabolism and excretion of cortisol [2] . Central to our hypothesis is that this increased metabolism and excretion of cortisol during adrenarche must be balanced by an increased production of cortisol. Rainey's group [3, 4] reported increasing immuno-intensity of CYP17 after age five and plateauing at age 13 in not just zona reticularis but also in zona fasciculata (ZF). Given that CYP17 has only 17α hydroxylase activity in the ZF [5] , this finding is consistent with an increased production of cortisol through adrenarche in normals. Adrenarche might then tip the balance in a patient with limited reserve for cortisol production, such as is in the case in our patient with 3βHSD2 deficiency. A state of cortisol insufficiency may thus ensue resulting in secondary elevation in ACTH, and the steroid picture characteristic of 3βHSD2 deficiency.
Case presentation
The patient born at term following an uncomplicated pregnancy in Brisbane was noted to have ambiguous genitalia with testes in the scrotum, a vaginal introitus, perineal urethra and a small phallus. The karyotype was 46XY. The diagnosis was presumed to be androgen insensitivity, although human chorionic gonadotropin (hCG) stimulation test commenced at 4 days of age was not consistent with this (Table 1) . Urine steroid profile by gas chromatography mass spectrometry at 5 days of age was not suggestive of congenital adrenal hyperplasia (CAH) due to 21-, 11-hydroxylase or 3β-hydroxy-steroiddehydrogenase type II (3βHSD2) deficiency (Table 2) . Assays for 17α-hydroxyprogesterone (17αOHP) and/or 17-hydroxypregnenolone (17OHpreg) do not appear to have been performed. She underwent laparoscopy at 13 days of age, revealing absent uterus and ovaries, and at the same time underwent gonadectomy. Histopathology of the testes were of 12 × 8 × 7 mm left testis and 14 × 7 × 5 mm right testis with unremarkable histology consistent with age and with no evidence of malignancy. Vas deferens and epididymal tissue were histologically normal.
DNA testing on the patient at 5 years of age and on the mother showed no mutations or deletions of the androgen receptor gene, though less than 50% of probands with partial androgen insensitivity syndrome will have pathogenic variants detected on sequencing of the AR gene.
Examination findings at 6 years of age noted labial folds, a 4 cm phallus and perineal urethra opening just above the vagina. Growth consistently followed the 50th percentile for weight and the 75th percentile for height. The patient identified as a female.
At 9 years of age the patient developed premature pubic hair, but no axillary hair. There were a few pimples but no acne. This evidence of early adrenarche was not in keeping with the diagnosis of androgen insensitivity syndrome. She was troubled by genital irritation secondary to 4 cm clitoromegaly and erections from 11 years of age. ACTH levels were up to 6 times the upper limit of normal, and hydrocortisone 8 mg mane was trialled to see whether suppression of ACTH stimulation of adrenal androgens might help minimise the clitoromegaly. ACTH did drop to three times the upper limit of normal, but the patient decided to cease hydrocortisone and undergo elective clitoral reduction at 14 years of age. Hyperpigmentation did not occur.
Hyperkalaemia in a haemolysed sample at 10.5 years of age prompted assessment of adrenal function. Urine steroid profile demonstrated elevated de-hydro-epiandrostenedione (DHEA), pregnanetriol and pregnentriol and low excretion of cortisol metabolites; cortisone and cortisol (Table 2 ). Given the XY genotype, these results were reported to be consistent with 3βHSD2 deficiency, although there was no quantification of pregnanetriol and no report of pregnentriolone for determination of their ratio, which is considered to be the best means of discriminating this disorder from 21-hydroxylase CAH. Consistent with the diagnosis, basal 17OHPreg was elevated, adrenal androgens were elevated, testosterone was normal and follicle stimulating hormone (FSH) was elevated (Table 3) . Interestingly there was relatively less effect on mineralocorticoids and glucocorticoids compared with sex steroids. 
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Not performed Not performed Table 2 : Urinary steroid analysis. Oestrogen hormone replacement therapy was commenced at 12.25 years of age, later than is typically done, and was up titrated relatively slowly. The patient ultimately reached 180.2 cm in height, significantly taller than the 171.5 cm predicted from mid-parental height. Her bone age at 16 years of age was 14 years, in keeping with low oestradiol levels resulting in delayed epiphyseal closure.
days old 10.years of age
The patient had minor breast development, but at 20 years of age sought breast augmentation. Bone mineral densitometry has been ordered to assess for any adverse effects from low oestradiol levels.
Next generation and Sanger sequencing at 21 years of age confirmed two variants in the HSD3B2 gene, c.244G>A (p.Ala82Thr) which has been previously described in patients with non-salt wasting classical 3βHSD2 deficiency [6] , and the novel 931C>T (p.Gln311*) variant in exon 4, which interrupts the reading frame and introduces a premature STOP codon at amino-acid position 311, likely resulting in a truncated protein product or degradation of the transcript via nonsense mediated decay. The latter variant has not been previously described in the literature, Human Gene Mutation Database or patients tested by our laboratory. Parental studies were not performed, but given the phenotype we feel we can assume these two variants are on separate alleles.
The patient has never required supplementation with glucocorticoids, and there were no significant symptoms or signs suggestive of mineralocorticoid insufficiency (although as-required fludrocortisone was initiated in light of some thirst and dizziness in hot weather).
The family felt the gonadectomy as an infant was rushed, with confusion over that decision throughout her childhood. Psychologist consultation at 14 years of age prior to clitoral reduction surgery opined the patient had a clear, unambivalent view that she is female, but with both male and female traits with which she was comfortable. This lack of ambivalence and confusion was felt to be a concern possibly relating to some level of denial or anxiety. Nonetheless she is now a well 21-year-old woman and is highly functioning, performing well at university and in her occupation. She is aware that gonadectomy as an infant means she cannot conceive children, and is not discontent in this knowledge. She has a sexual interest in males and is successfully pursuing vaginal dilatation.
Discussion
This is a case of 46XY disorder of sexual development that was misdiagnosed. It raised a number of discussion points.
Epidemiology
3βHSD2 deficiency accounts for less than 5% of CAH worldwide [7] . Its prevalence is too low to be accurately estimated, although rates are much higher in populations with high rates of consanguinity. The cause of 46XY ambiguous genitalia varies in different populations, and in many cases a secure diagnosis is not made. It has been suggested that epigenetic variations or environmental factors play a role [8] .
Inconsistency between the severe effects on androgen production and the relatively mild effects on glucocorticoid and mineralocorticoid production
There have been more than 40 mutations reported in the HSD3B2 gene affecting enzyme activity to varying degrees [9] . The in vitro enzyme activity of the mutant enzyme is mostly in keeping with the degree of salt wasting [9, 10] . Our patient exhibited evidence of inadequate in-utero exposure to testosterone and dihydro-testosterone, but exhibited only minor effects on mineralocorticoids and glucocorticoids, potentially obscuring the diagnosis of 3βHSD2 deficiency in CAH. As was the case with our patient, the degree of salt wasting does not correlate with the impairment in male sexual differentiation, which can range from hypospadias to ambiguous genitalia [10] . Neither does the degree of salt wasting correspond to serum testosterone levels, with both low and high neonatal serum testosterone levels reported in cases of salt wasting and simple virilising forms [9, [11] [12] [13] [14] .
There are multiple pathways for androgen biosynthesis in the gonads that are essential for normal male sexual differentiation [15] . There are also multiple pathways for peripheral conversion of androgens to active forms [16] . It may be that inter-individual variability in these pathways and the androgen targets may explain the variable disorders of sexual differentiation (DSD) phenotype on patients with 3βHSD2 deficiency and other forms of CAH.
The misdiagnosis
There was a failure to make the correct diagnosis as a neonate in our patient.
According to the UK guidelines for diagnosis of disorders of sexual differentiation patients with 3βHSD2 deficiency typically demonstrate low testosterone, low testosterone response to hCG with elevated DHEA, DHEAS and androstenedione, an abnormal short synacthen test and abnormal urinary steroid profile [17] . Whilst there are hormonal criteria proposed for the diagnosis of 3βHSD2 deficiency, based on ACTH-stimulated 17OHPreg and 17OHPreg : cortisol ratios [18, 19] , urinary steroids tend to be used instead.
hCG stimulation testing is often done for diagnostic management of 46XY DSD despite having poor utility in distinguishing patients with disorders of androgen synthesis from disorders of androgen action [8] . A diagnosis of partial androgen insensitivity was presumably based on an abnormally elevated basal free testosterone despite an abnormal response to hCG stimulation testing, which may have reflected a lack of confidence in the test and high pre-test probability of androgen insufficiency as the diagnosis. A free testosterone immunoassay is unreliable, particularly at the low concentrations seen in the neonatal population. We suggest that the basal free testosterone in our patient was falsely elevated due to laboratory error, and hCG stimulation test was either misinterpreted or felt it to be unreliable.
The presence of peripheral 3βHSD type I activity often complicates the diagnosis of this disorder as very high levels of 5-ene steroids (DHEA, 17-hydroxypregnenolone and pregnenolone) may be converted extra-adrenally to 4-ene steroids (androstenedione, 17OHP and progesterone) thus suggesting the diagnosis of 21-hydroxylase deficiency. Urinary steroids have been shown to discriminate 3βHSD2 deficiency from 21-hydroxylase deficiency and normals in the neonate, based on high ratios of pregnenetriol : cortisol metabolites or pregnenetriol : pregnetriolone [20] . The urinary steroid profile in our case as a neonate did not demonstrate any excess metabolites of adrenal steroids, which is inconsistent with the urinary steroid profile performed at 10.5 years of age, where there were clear abnormalities. The adrenal produces approximately two thirds of fetal cortisol towards the end of a pregnancy, with the remainder being derived maternally. Urinary steroids drop in normal neonates within the first week of life [21] , after maternal-derived steroids have been excreted. If there was an inability of the neonatal adrenal gland to produce adequate cortisol then a compensatory rise in ACTH should be anticipated within the first week of life. The normal day 5 urinary steroid pattern in our patient suggests that she was producing adequate cortisol as a neonate.
How then can the inconsistency in urinary steroid pattern at the two time points be explained? The patient's mother was not exposed to β-methasone prior to delivery [22] . One hypothesis is the inconsistency in urinary steroid pattern is related to the changes in adrenal steroidogenic enzyme expression at adrenarche. The zona reticularis in the adult adrenal gland has very low expression of 3βHSD2 and high greater expression of enzymes higher in the steroidogenesis pathway. The zona reticularis expands and the expression of 3βHSD2 in the zona reticularis has been demonstrated to decline through a normal childhood into adrenarche [9] . This may explain the increased concentrations of DHEAS seen at adrenarche. It might be anticipated that with reduced enzyme activity associated with a mutated HSD3B2 gene, an exaggerated or early adrenarche occurs. This would account for the premature development of pubic hair in our patient. Another adrenal enzyme that markedly alters expression during adrenarche is CYP17. It increases in expression in not just the zona reticularis but also the zona fasciculata where it has only 17α hydroxylase activity, in keeping with an increase in cortisol production [5, 18, 23] . Cortisol metabolism is known to increase through puberty due to increased activity of 11-β-hydroxysteroid dehydrogenase type I and increased glomerular filtration rate [2] . It may then be hypothesised that the enzyme product of a mutated HSD3B2 gene in the zona fasciculata becomes rate limiting for cortisol production when the cortisol production rate increases at adrenarche.
Should this hypothesis be correct, then even with an improved testosterone assay, the recent UK guidelines for determining aetiology of disorders of sexual development would still misdiagnose this condition. At birth there would have been an adequate cortisol response to synacthen, resulting in an incorrect diagnosis of 17-β-hydroxysteroid dehydrogenase type III (17βHSD3) deficiency CAH. Incidentally 17βHSD3 looks phenotypically very similar to 3βHSD2, both virilising at adrenarche. The mechanism for virilisation of 46XY patients with 17βHSD3 deficiency at adrenarche is unknown, but has been hypothesised that elevated androstenedione is converted to more active androgens by increased expression of 17βHSD type V in muscle at adrenarche [24] . It may be that the same mechanism is responsible for adrenarchal virilisation in 3βHSD2 deficiency.
The role and timing of surgery
46XY with 3βHSD2 deficiency raised as males are unlikely to be fertile but have a low risk of malignancy [13] . According to the 2006 consensus statement, children with 46XY DSD should be raised as male if there is evidence of androgen responsiveness, including phallic development, or as female if potential for androgen responsiveness is lacking [25] , but the decision regarding gender assignment should also consider specific diagnosis, genital anatomy, surgical options, potential for fertility, potential for adult sexual responsiveness function and factors that may predict most likely adult gender identity.
A recent publication has added 3βHSD2 deficiency to the short list of conditions associated with spontaneous virilisation at puberty of patients with 46XY karyotype [13] . Remarkably, there have even been reports of spermatogenesis in males with moderate to severe DSD resulting from 3βHSD2 deficiency. This adds weight to the argument that testes should be retained until a definite gender preference becomes clear.
Conclusions
There was a failure to make the correct diagnosis as a neonate in our patient for a number of reasons: false elevation of the basal free testosterone, misinterpretation or lack of confidence in the accuracy of the hCG stimulation test (demonstrating no testosterone increment), and negative urinary steroid profile which was inconsistent with the published criteria for diagnosis of CAH. We suggest that this is a result of adrenarche unmasking the condition by driving cortisol production to rates that cause the mutant 3βHSD2 enzyme to become rate limiting for cortisol production. The sequelae from the misdiagnosis in this case include a potential for virilisation and fertility that was not recognised, gender assignment forced by gonadectomy, and significant distress to the family.
We suggest that a gene panel be performed in all cases of disorders of sexual development.
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